Des-gamma-carboxy prothrombin (DCP) is a blood biomarker used to assess hepatocellular carcinoma (HCC), the most common primary liver cancer. DCP is also called protein induced by vitamin K absence or antagonist-II (PIVKA-II). HCC cells can produce an abnormal form of prothrombin because vitamin K-dependent carboxylation is incomplete, causing DCP to accumulate in the blood. A high DCP level can increase suspicion for HCC and may also correlate with tumor burden or aggressive tumor features, but it is not specific enough to diagnose cancer by itself. Vitamin K deficiency, warfarin therapy, impaired bile flow, and some severe liver conditions can also raise DCP. For that reason, clinicians interpret the result with liver imaging, AFP, AFP-L3, medication history, and evidence of cholestasis or malnutrition. Serial DCP results can be useful after treatment when the marker was elevated at diagnosis.
- DCP and PIVKA-II are two names for the same abnormal prothrombin biomarker.
- A commonly used research or clinical cutoff is about 40 mAU/mL, but assay-specific reference ranges differ.
- High DCP may occur with HCC, but vitamin K deficiency, warfarin, and biliary obstruction can also raise it.
- DCP should not be used alone to diagnose or rule out liver cancer.
- Falling DCP after HCC treatment can support response when imaging and other markers show the same trend.
Table of Contents
- What DCP Is and Why It Rises
- DCP Normal Range and Cutoffs
- How DCP Is Used in HCC
- DCP Versus AFP and AFP-L3
- Noncancer Causes of High DCP
- Monitoring DCP After HCC Treatment
- Next Steps After a High DCP Result
What DCP Is and Why It Rises
Normal prothrombin is a clotting protein made by the liver. Before it functions properly, several glutamic acid residues must be carboxylated in a vitamin K-dependent process. DCP is an incompletely carboxylated form of prothrombin. HCC cells often have altered vitamin K handling or carboxylation machinery, so they may release more DCP than normal hepatocytes.
This biology is why DCP can act as a tumor marker. It reflects a different process from alpha-fetoprotein (AFP), which is a fetal protein re-expressed by some HCCs. One tumor may release AFP, another may release DCP, and a third may release both or neither. The markers therefore provide complementary rather than redundant information.
Laboratories may report DCP in mAU/mL or, less commonly, in ng/mL depending on the assay. This matters because numbers from different unit systems are not directly interchangeable. Always use the reference interval printed on the report.
In many clinical and research settings, DCP is grouped with AFP and AFP-L3 as part of a liver cancer biomarker panel. That combined approach can help with risk assessment, but the diagnosis of HCC still depends mainly on appropriate imaging criteria or pathology.
DCP Normal Range and Cutoffs
There is no single universal DCP cutoff that applies to every assay and every purpose. A threshold near 40 mAU/mL is often used in studies and clinical practice, while some laboratories use different decision points. Higher thresholds usually improve specificity but reduce sensitivity, meaning fewer false positives but more missed cancers.
| Result pattern | What it may suggest | What clinicians usually check |
|---|---|---|
| Within reference range | No DCP elevation detected | Does not exclude HCC; continue risk-appropriate imaging |
| Mild elevation | Could reflect HCC or a noncancer vitamin K-related cause | Medication use, bilirubin, cholestasis, nutrition, repeat testing |
| Marked elevation | More concerning for HCC in the right clinical setting | Contrast CT or MRI, AFP, AFP-L3, staging evaluation |
| Rising serial values | May indicate increasing tumor activity | Compare with imaging and treatment timeline |
| Falling after therapy | Can support treatment response | Confirm with radiographic response |
A cutoff should never be interpreted without context. For example, a DCP of 60 mAU/mL in a person taking warfarin may have a very different meaning from the same result in a person with cirrhosis, no vitamin K antagonist exposure, and a new arterial-enhancing liver mass.
The reference range may also differ between DCP and PIVKA-II branded assays even though they measure the same biological concept. When monitoring a trend, using the same laboratory and method improves comparability.
How DCP Is Used in HCC
DCP can support three main clinical tasks: risk stratification, characterization of known HCC, and treatment monitoring.
For surveillance, DCP alone is not sensitive enough to replace established HCC surveillance. In the United States, major guidance still centers on ultrasound with AFP for appropriate at-risk populations, usually at six-month intervals. DCP and AFP-L3 are recognized as promising complementary biomarkers and are used more extensively in some regions, but guidance distinguishes them from the standard surveillance backbone.
Once HCC is diagnosed, a high DCP may provide prognostic information. Studies have associated higher concentrations with larger tumors, vascular invasion, intrahepatic spread, and more aggressive biology. These are statistical associations, not certainties for an individual patient. Imaging remains necessary to determine tumor size, number, vessel involvement, and spread.
DCP can also be helpful in AFP-negative HCC. A person may have a normal AFP but a high DCP, which is one reason clinicians sometimes order both. The reverse can also happen.
After treatment, DCP can be followed if it was elevated beforehand. A decline may support that viable tumor burden has fallen, while a new rise may prompt earlier imaging. This is most useful when the marker has shown a clear relationship with the person’s disease over time.
DCP Versus AFP and AFP-L3
DCP, AFP, and AFP-L3 reflect different aspects of HCC biology.
- AFP measures total alpha-fetoprotein. It is the most established serum marker used with ultrasound in HCC surveillance, but hepatitis activity and liver regeneration can also raise it.
- AFP-L3% measures the proportion of AFP with a specific lectin-binding glycosylation pattern associated more strongly with HCC. A cutoff near 10% is commonly used, depending on assay.
- DCP/PIVKA-II measures abnormal prothrombin related to impaired vitamin K-dependent carboxylation.
Because they differ biologically, combining them can improve sensitivity compared with relying on one marker. The GALAD model combines gender, age, AFP, AFP-L3, and DCP and has shown promising diagnostic performance in research cohorts. Even so, biomarker algorithms are not a substitute for diagnostic imaging when a suspicious lesion is present.
Readers comparing the two specialized liver markers can review the AFP-L3 test separately. The key distinction is that AFP-L3 is expressed as a fraction of AFP, whereas DCP is a different protein measurement with its own confounders.
Noncancer Causes of High DCP
DCP can rise when the body cannot complete vitamin K-dependent carboxylation even without cancer. This is the test’s most important source of false-positive interpretation.
Common confounders include:
- Warfarin or other vitamin K antagonism. Warfarin intentionally blocks vitamin K recycling and can markedly increase abnormal prothrombin production.
- Vitamin K deficiency. Poor intake, malabsorption, prolonged antibiotic use, and severe illness can reduce vitamin K availability.
- Biliary obstruction or cholestasis. Bile is needed for absorption of fat-soluble vitamins, including vitamin K. Obstruction can therefore raise DCP indirectly.
- Severe liver dysfunction. Advanced hepatic disease may alter clotting-factor synthesis and vitamin K handling.
This is why a high DCP result should trigger a medication and nutrition review. Bilirubin, alkaline phosphatase, prothrombin time/INR, and imaging of the biliary system may help distinguish a vitamin K-related elevation from tumor-related production.
A useful clinical clue is whether the result changes after the noncancer cause is corrected. If DCP falls after relief of biliary obstruction or correction of vitamin K deficiency, that supports a confounding explanation. However, a response to vitamin K does not by itself exclude HCC, especially in a person at high baseline risk.
Pregnancy is not a typical reason to order DCP for HCC assessment, and DCP should not be treated as a general liver-function test. It has a specific role in liver-cancer biomarker evaluation.
Monitoring DCP After HCC Treatment
A biomarker is most useful for monitoring when it was clearly abnormal before treatment. If DCP was elevated at diagnosis, clinicians may recheck it after surgery, ablation, transarterial therapy, radiation, or systemic treatment.
The ideal post-treatment pattern is usually a substantial decline toward the normal range, but the timing depends on treatment type and baseline level. A single early post-treatment measurement may be difficult to interpret because tumor-cell death, liver inflammation, and changing vitamin K status can temporarily affect results.
Serial monitoring works best when three data streams agree:
- DCP trend is falling or stable.
- Other markers, such as AFP or AFP-L3, move in the same direction if they were elevated.
- Imaging shows treatment response and no new lesions.
Discordance deserves attention. A rising DCP with stable imaging does not prove recurrence, but it may justify closer review or earlier repeat imaging. Likewise, a falling DCP should not override imaging that shows viable or enlarging tumor.
The marker is less useful for a patient whose DCP was normal despite active HCC. In that situation, another marker or imaging may be a better personalized follow-up tool.
Next Steps After a High DCP Result
The next step is determined by the patient’s HCC risk and by whether a benign explanation is plausible. A clinician typically reviews the following before deciding how urgently to investigate:
- cirrhosis, hepatitis B, hepatitis C history, or other chronic liver disease;
- warfarin or other medications affecting vitamin K;
- jaundice or laboratory evidence of cholestasis;
- nutritional status or malabsorption;
- AFP and AFP-L3 results;
- the most recent liver ultrasound, CT, or MRI; and
- prior HCC treatment.
In a high-risk patient with a suspicious lesion, contrast-enhanced multiphasic CT or MRI is usually the key diagnostic step. In cirrhosis or certain chronic hepatitis B settings, HCC can often be diagnosed by characteristic imaging without biopsy. DCP may strengthen concern but cannot establish the diagnosis alone.
If imaging is normal and a reversible cause is likely, the clinician may address that cause and repeat DCP. If the marker remains high or rises, the threshold for further imaging becomes lower.
The practical message is to treat DCP as one piece of a probability estimate. It is neither a yes-or-no cancer test nor an incidental number to ignore. The result has the greatest value when it changes a concrete next step: repeat testing, correction of a confounder, earlier imaging, or closer post-treatment follow-up.
Why units and assay method matter
DCP/PIVKA-II reports are not always directly comparable because laboratories may use different assays and unit systems. Many laboratories report mAU/mL, while some literature describes ng/mL. There is no simple universal conversion that patients should apply on their own. A value should be interpreted against the reference interval and decision threshold supplied with that specific method.
This issue becomes especially important during long-term HCC follow-up. If a patient moves between hospitals and the DCP number changes abruptly, the first question should be whether the assay or units changed. A laboratory-method change can create an apparent jump even when tumor biology is stable. Whenever possible, clinicians compare serial values from the same platform or review the methods before interpreting a trend.
Vitamin K correction can clarify a confounder but is not a cancer test
When vitamin K deficiency is plausible, correcting the deficiency can help clarify why DCP is elevated. For example, a patient with prolonged cholestasis, poor oral intake, and an elevated INR may have impaired vitamin K absorption. After biliary drainage and appropriate vitamin K replacement, DCP may fall substantially.
That response supports a non-tumor contribution, but it does not function as a definitive “vitamin K challenge” that rules cancer in or out. A patient can have both HCC and vitamin K deficiency at the same time. Imaging remains necessary when HCC risk is high or a liver lesion is suspicious.
Warfarin creates a particularly strong confounder because its therapeutic purpose is to inhibit vitamin K recycling. In a patient taking warfarin, DCP may be unsuitable for cancer interpretation, and the oncology team may rely more heavily on AFP, AFP-L3, and imaging.
How DCP behaves in different treatment settings
The timing of DCP decline can vary after HCC therapy. After surgical resection or thermal ablation of a marker-producing tumor, a substantial fall is expected if all active marker-producing tissue has been removed. After transarterial chemoembolization, radioembolization, radiation, or systemic therapy, the decline may be slower or uneven because viable and treated tumor can coexist for a period of time.
A temporary plateau does not automatically mean treatment failed. Radiographic criteria for HCC often focus on viable enhancing tumor rather than size alone, and biomarker trends are interpreted alongside those imaging features. Likewise, a dramatic DCP fall should not be used to declare complete response if imaging still shows viable enhancement.
DCP can also be useful when AFP never rose. In that situation, DCP may become the patient’s best serum marker. The reverse is equally true: if DCP stayed normal despite active HCC, there is little reason to force it into follow-up simply because it is a recognized biomarker.
Practical interpretation examples
A DCP of 150 mAU/mL in a patient with cirrhosis, normal vitamin K status, no warfarin exposure, and a new 2-cm arterial-enhancing liver lesion is clinically concerning. The same number in a patient with severe obstructive jaundice and prolonged antibiotic use requires a much more cautious interpretation.
A second example is a patient whose DCP fell from 2,000 to 90 mAU/mL after therapy while MRI shows major loss of viable tumor. That combined pattern strongly supports response even though the marker has not normalized. A later rise from 90 to 300 to 800 mAU/mL would be more concerning than one isolated value of 120.
These examples show why DCP is best used as a trend marker embedded in the clinical timeline. The number becomes meaningful only after the clinician accounts for vitamin K biology, treatment timing, liver function, and imaging.
Why DCP is used differently across countries
Clinical use of DCP/PIVKA-II varies by region. In Japan and other parts of Asia, it has a longer history in HCC detection and monitoring, often alongside AFP and AFP-L3. In the United States, major guidance has been more cautious about using DCP as a routine stand-alone surveillance test because early-stage sensitivity is insufficient.
This difference does not mean the biomarker is valid in one country and invalid in another. It reflects different guideline evidence thresholds, surveillance systems, assays, and clinical traditions. Patients comparing recommendations from different health systems should focus on the local guideline and the purpose for which the test is being used.
Bottom-line interpretation
DCP is most valuable when the patient’s tumor clearly produces it and when vitamin K-related confounders are absent. A trend that matches imaging can strengthen confidence in response or recurrence assessment. A value obtained during warfarin therapy, severe cholestasis, or vitamin K deficiency deserves much less weight. That context-sensitive approach is more accurate than treating a single cutoff as a universal cancer boundary.
References
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma 2023 (Guideline)
- Existing and emerging biomarkers in hepatocellular carcinoma: relevance in staging, determination of minimal residual disease, and monitoring treatment response: a narrative review 2023 (Review)
- Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma 2024 (Review)
- Hepatocellular Carcinoma: The Search for an Optimal Screening Test 2025 (Review)
Disclaimer
DCP/PIVKA-II cannot diagnose or exclude hepatocellular carcinoma on its own. Results should be interpreted by a clinician using the assay-specific reference range, medications, vitamin K status, liver imaging, and other tumor markers. Urgent evaluation is appropriate for severe jaundice, vomiting blood, confusion, rapidly increasing abdominal swelling, or other signs of serious liver disease.
